Objective: Atorvastatin therapy is now recommended for reduction of cardiovascular risk in type 2 diabetic patients (T2DM), based on convincing evidence of reductions in mortality and vascular events in major clinical outcome trials. The aim is to evaluate the effects of atorvastatin on proinflammatory markers (TNF-α, IL-6), HbA1c andleptin in obese patients with type 2 diabetes. Methods: Sixty fivenewly diagnosed T2DM patients were randomly allocated into 2 groups; group I treated with metformin only; in group II atorvastatin was added with metformin. Twenty healthy subjects were enrolled as control group. While maintaining their usual eating habits, fasting blood samples were collected at baseline and after 12 weeks of treatment. Results: HbA1c levelswere decreased significantlyonly in group I compared with baseline value; while serum levels of leptin, TNF-α and IL-6 were decreased significantly in both groups compared to baseline values. Conclusion: Atorvastatin is effective in reducing leptin and pro-inflammatory cytokines levels but associated with an increased risk of worsening HbA1c in patients with T2DM.
